



Translation

Notice: This document is a translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

October 14, 2025

To Whom It May Concern:

Company Name: Daito Pharmaceutical Co., Ltd.
Representative: Hiroshi Matsumori, President and CEO
(Securities Code: 4577, Prime Market of Tokyo Stock Exchange)
Inquiries: Kenji Otsuga, Executive Officer, CFO
(Telephone Number: +81-76-421-5665)

Notice Regarding the Results of the Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase Transaction (ToSTNeT-3) and the Completion of the Acquisition of Treasury Shares

Daito Pharmaceutical Co., Ltd. (the “Company”) hereby announces that, with respect to the acquisition of treasury shares announced on October 10, 2025, the Company has purchased shares as outlined below. In addition, the acquisition of treasury shares through off-auction own share repurchase transaction (ToSTNeT-3), based on the resolution of the Board of Directors at the meeting held on October 10, 2025, has been completed with today’s acquisition.

1. Reason for acquisition of treasury shares

The Company has acquired treasury shares as part of its capital policy under the Medium-Term Management Plan, with the aim of enhancing shareholder returns and improving capital efficiency.

2. Details of acquisition

- | | |
|---------------------------------------|--|
| (1) Class of shares acquired: | Common stock of the Company |
| (2) Total number of shares acquired: | 242,000shares
(Equivalent to 0.8% of the total number of shares issued, excluding treasury shares) |
| (3) Total acquisition cost of shares: | ¥286,528,000 |
| (4) Acquisition date: | October 14, 2025 |
| (5) Method of acquisition: | Acquisition through off-auction own share repurchase transaction (ToSTNeT-3) of the Tokyo Stock Exchange |

(Reference)

Details of the resolution on the acquisition of treasury shares at the meeting of the Board of Directors held on October 10, 2025

- | | |
|--|--|
| ● Class of shares to be acquired: | Common stock of the Company |
| ● Total number of shares to be acquired: | Up to 250,000 shares
(Equivalent to 0.8% of the total number of shares issued, excluding treasury shares) |
| ● Total acquisition cost of shares: | Up to ¥296,000,000 |
| ● Acquisition date: | October 14, 2025 |

3. Status of treasury shares after the completion of this purchase (for reference)

- (1) Total number of shares issued (excluding treasury shares): 29,838,366 shares
- (2) Number of treasury shares: 258,514 shares

Note: The above number of treasury shares does not include 94,340 shares of the Company held in trust under the stock delivery trust for Board Directors.

(This is a reference figure obtained by adding the number of treasury shares held as of September 30, 2025 to the treasury shares acquired in 2. above.)

4. Cancellation of treasury shares

At the meeting of the Board of Directors held on October 10, 2025, the Company resolved to cancel 242,000 shares of treasury shares acquired as stated in 2. above, effective May 29, 2026.

As a result of this cancellation, the total number of shares issued is scheduled to be 29,854,880 shares.

End